Interesting PM Put And Call Options For February 2026

Philip Morris International (PM) is trading at $161.25 and Stock Options Channel highlights a $160 put (bid $4.60) that would set an effective purchase basis of $155.40 if sold-to-open, with a 55% probability of expiring worthless and a 2.88% return (23.85% annualized) if it does. On the call side, a $165 covered call (bid $3.00) would produce a 4.19% total return if called at the Feb 2026 expiration, with a 57% chance of expiring worthless and a 1.86% yield boost (15.43% annualized). Implied volatilities are ~27% (put) and ~30% (call) versus a trailing 12‑month volatility of 26%, and the piece frames these option choices as yield-enhancing trade ideas relative to the current share price.

Analysis

Market structure: Short-dated options sellers and income-focused equity holders are the immediate beneficiaries — selling the Feb‑2026 $160 put (collect $4.60) or the $165 covered call (collect $3.00) offers a ~1.9–2.9% one‑time yield boost with ~55–57% modeled odds of expiring worthless. That activity effectively creates a liquidity/support band around $160–$165 for PM as sellers are cash‑committed to buy, tightening effective sell pressure and reducing free float near those strikes. Dealers and volatility sellers capture the theta but face asymmetric downside if regulatory shocks occur.

Risk assessment: Tail risks are regulatory/litigation/excise‑tax shocks that can erase >20–30% (single‑event) and are not reflected in current IV (27–30% vs realized 26%). Immediately (days) option skew and small IV edge favors selling premium; over months the Feb‑2026 horizon concentrates gamma risk into earnings/FDA rulings. Hidden dependencies include FX exposure (EM revenues), tobacco‑policy calendars, and correlated capital‑flows into defensive sectors that could reverse quickly on policy headlines.

Trade implications: Direct plays—cash‑secured put sell at $160 (premium = $4.60) or buy 100 shares and sell $165 call to harvest ~4.2% to cap upside through Feb‑2026; if assigned, convert to covered call/collar. Use collars or protective puts for downside beyond 8–12% and size such that one contract ≈1% portfolio. Pair idea: long PM vs short MO (Altria) to capture international pricing power and lower U.S. regulatory concentration through 2026.

Contrarian angles: The market underprices regulatory tail risk so pure premium selling is vulnerable to regime moves; implied vol only modestly above realized suggests protection is cheap and should be bought if you cannot accept a 20% drawdown. Historical parallels (tobacco regulatory episodes) show rapid >20% de‑risings; structured income trades should have hard stop/hedge rules and roll plans rather than rely solely on modeled 55–57% odds.

Key Decisions for Investors

• Sell cash‑secured PM Feb‑2026 $160 puts (collect ~$4.60) sized to 1% of portfolio per contract (cash commitment $16,000 per contract). Target cost basis if assigned $155.40. If PM < $150 within 60 days, buy‑to‑close or roll down to $150+$1.00 credit; trim exposure if PM trades < $145.
• Establish a covered‑call income position: buy 100 shares PM and sell Feb‑2026 $165 calls (collect ~$3.00) for a capped gross return ~4.2% to expiry. Size 1–2% portfolio, roll up/forward if PM > $170 or if calls become ITM with >30 days left; buy a Feb‑2026 $150 put if downside protection required (convert to collar).
• Purchase tail protection if net short option premium exposure >0.5% portfolio: buy Feb‑2026 $140–$150 puts to cap catastrophic losses (>12–15%). Allocate 0.2–0.5% portfolio to this hedge and reprice after major regulatory/FDA news.
• Implement a pair trade: long PM (2% position) and short MO (Altria) (1.5% position) through 2026 to express international pricing power vs U.S. regulatory concentration. Close if relative spread tightens to 0% or widen to +10% outperformance, or on bilateral regulatory catalysts.